文献速递角膜与眼表疾病眼底病与葡萄膜炎

噬菌体衍生外溶素P128抗氟喹诺酮耐药MRSA角膜炎的研究

Bacteriophage-derived ectolysin: a promising antimicrobial against fluoroquinolone-resistant MRSA.
PubMed 文献 · Br J Ophthalmol · 2026-10-22

本研究评估噬菌体K来源的肽聚糖降解酶P128对多重耐药金黄色葡萄球菌的抗菌活性,并在兔角膜伤口模型中验证眼部安全性,在兔和小鼠感染性角膜炎模型中验证疗效。P128对临床分离菌株的最小抑菌浓度为0.5至16 µg/mL,局部滴眼不影响角膜再上皮化且无不良反应,在兔模型中疗效与加替沙星相当,在小鼠氟喹诺酮耐药MRSA角膜炎模型中降低细菌负荷和角膜水肿。

要点

  • P128对感染性角膜炎患者来源的多重耐药金黄色葡萄球菌有强效抗菌活性
  • P128局部滴眼不干扰兔角膜再上皮化且无不良反应
  • P128与膜活性抗菌肽联用可根除96小时预形成生物膜

核心结论

  • P128对耐药MRSA角膜炎具有治疗潜力,与抗菌肽联用可能扩展针对生物膜相关感染的抗菌武器库。

研究设计与样本

  • 体外测定P128对多重耐药金黄色葡萄球菌临床菌株的抗菌活性,并在兔角膜伤口愈合模型中评估眼部安全性。
  • 在兔和小鼠感染性角膜炎模型中研究P128的抗菌疗效。

主要发现

  • P128对感染性角膜炎患者来源的多重耐药金黄色葡萄球菌菌株的最小抑菌浓度为0.5 µg/mL至16 µg/mL。
  • 兔损伤角膜局部滴用P128不干扰再上皮化速率,也未引起任何不良反应。
  • 在兔金黄色葡萄球菌角膜炎模型中,P128疗效与标准治疗抗生素加替沙星相似。
  • 在小鼠氟喹诺酮耐药MRSA角膜炎模型中,P128降低细菌负荷和角膜水肿。
  • P128与膜活性抗菌肽显示强效协同作用,其组合根除了预形成的96小时生物膜。

关键数值与推荐

  • P128对多重耐药金黄色葡萄球菌临床菌株的最小抑菌浓度范围为0.5 µg/mL至16 µg/mL。
  • P128与膜活性抗菌肽联用可根除预形成的96小时生物膜。

临床怎么用

  • P128有望作为耐药MRSA角膜炎的候选治疗药物,尤其在与抗菌肽联用时可能针对生物膜相关感染。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Microbial keratitis remains one of the leading causes of blindness globally. With the rising threat of antimicrobial resistance, there is an urgent need for the development of novel antimicrobial agents with innovative mechanisms of action. MATERIAL AND METHODS: Antibacterial properties of P128, a peptidoglycan degrading enzyme derived from bacteriophage K, was determined against multi-drug resistant Staphylococcus aureus clinical strains. P128 was tested for its ocular safety in a rabbit corneal wound healing model. The antibacterial efficacy of P128 was investigated in in vivo rabbit and mouse infectious keratitis models. RESULTS: P128 demonstrated potent antibacterial activity against multidrug resistant S. aureus strains collected from patients with infectious keratitis, with minimum inhibitory concentrations ranging from 0.5 µg/mL to 16 µg/mL. Topical instillation of P128 to an injured cornea did not interfere with the re-epithelialisation rates nor cause any adverse effects. In a rabbit S. aureus keratitis model, P128 showed similar therapeutic efficacy to standard of care antibiotic, gatifloxacin. In a mouse model of fluoroquinolone-resistant methicillin-resistant S. aureus (MRSA) keratitis, P128 decreased the bacterial bioburden as well as corneal oedema. P128 displayed potent synergism with membrane active antimicrobial peptides, and their combination eradicated the preformed 96 hours biofilms. CONCLUSION: These results demonstrate the therapeutic potential of P128 for the management of drug-resistant MRSA keratitis and its combination with antimicrobial peptides may expand the antimicrobial armamentarium against biofilm-associated infections.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Low SWY, Tun Aung T, Venkatesh M, et al. Bacteriophage-derived ectolysin: a promising antimicrobial against fluoroquinolone-resistant MRSA. Br J Ophthalmol. 2026. PMID: 42618334. doi:10.1136/bjo-2026-329771

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。